Combination of Cetuximab and NK Immunotherapy for Recurrent Non-small Cell Lung Cancer
Status:
Completed
Trial end date:
2019-07-01
Target enrollment:
Participant gender:
Summary
The aim of this study is the safety and efficacy of Cetuximab plus natural killer(NK)
immunotherapy to recurrent non-small cell lung cancer with EGFR mutation.